Application of an Integrated GPCR SAR-Modeling Platform to Explain the Activation Selectivity of Human 5-HT2C over 5-HT2B

ACS Chemical Biology

Volumn 11, Issue 5, 2016, Pages 1372-1382

  Heifetz, Alexander ^a   Storer, R Ian ^b   McMurray, Gordon ^c   James, Tim ^a   Morao, Inaki ^a   Aldeghi, Matteo ^d   Bodkin, Mike J ^a   Biggin, Philip C ^d  

^a Evotec (UK) Ltd   (United States)

^b Pfizer Worldwide Research   (United States)

^c Worldwide Cardiovascular Group   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; MEMBRANE PROTEIN; SEROTONIN 2 AGONIST; SEROTONIN 2B RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; AZEPINE DERIVATIVE; SEROTONIN AGONIST;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CHEMICAL MODEL; CRYSTAL STRUCTURE; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; SEQUENCE ALIGNMENT; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY; CHEMISTRY; DRUG DESIGN; HUMAN; METABOLISM; PROTEIN CONFORMATION;

AMINO ACID SEQUENCE; AZEPINES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; PROTEIN CONFORMATION; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN RECEPTOR AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84971264657     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/acschembio.5b01045     Document Type: Article

References (45)

1. McCorvy, J. D. and Roth, B. L. (2015) Structure and function of serotonin G protein-coupled receptors Pharmacol. Ther. 150, 129-142 10.1016/j.pharmthera.2015.01.009
2. Roth, B. L. (2007) Drugs and valvular heart disease N. Engl. J. Med. 356, 6-9 10.1056/NEJMp068265
3. Tautermann, C. S. (2014) GPCR structures in drug design, emerging opportunities with new structures Bioorg. Med. Chem. Lett. 24, 4073-4079 10.1016/j.bmcl.2014.07.009
4. Shonberg, J., Kling, R. C., Gmeiner, P., and Lober, S. (2015) GPCR crystal structures: Medicinal chemistry in the pocket Bioorg. Med. Chem. 23, 3880-3906 10.1016/j.bmc.2014.12.034
5. Jazayeri, A., Dias, J. M., and Marshall, F. H. (2015) From G Protein-coupled Receptor Structure Resolution to Rational Drug Design J. Biol. Chem. 290, 19489-19495 10.1074/jbc.R115.668251
6. Jacobson, K. A. (2015) New paradigms in GPCR drug discovery Biochem. Pharmacol. 98, 541 10.1016/j.bcp.2015.08.085
7. Heifetz, A., Chudyk, E., Gleave, L., Aldeghi, M., Cherezov, V., Fedorov, D. G., Biggin, P. C., and Bodkin, M. (2015) The Fragment Molecular Orbital Method Reveals New Insight into the Chemical Nature of GPCR-Ligand Interactions J. Chem. Inf. Model. 56, 159 10.1021/acs.jcim.5b00644
8. Storer, R. I., Brennan, P. E., Brown, A. D., Bungay, P. J., Conlon, K. M., Corbett, M. S., DePianta, R. P., Fish, P. V., Heifetz, A., Ho, D. K., Jessiman, A. S., McMurray, G., de Oliveira, C. A., Roberts, L. R., Root, J. A., Shanmugasundaram, V., Shapiro, M. J., Skerten, M., Westbrook, D., Wheeler, S., Whitlock, G. A., and Wright, J. (2014) Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT(2)C) receptor agonists with exquisite functional selectivity over 5-HT(2)A and 5-HT(2)B receptors J. Med. Chem. 57, 5258-5269 10.1021/jm5003292
9. Tye, H., Mueller, S. G., Prestle, J., Scheuerer, S., Schindler, M., Nosse, B., Prevost, N., Brown, C. J., Heifetz, A., Moeller, C., Pedret-Dunn, A., and Whittaker, M. (2011) Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders Bioorg. Med. Chem. Lett. 21, 34-37 10.1016/j.bmcl.2010.11.089
10. Heifetz, A., Barker, O., Verquin, G., Wimmer, N., Meutermans, W., Pal, S., Law, R. J., and Whittaker, M. (2013) Fighting obesity with a sugar-based library: discovery of novel MCH-1R antagonists by a new computational-VAST approach for exploration of GPCR binding sites J. Chem. Inf. Model. 53, 1084-1099 10.1021/ci4000882
11. Heifetz, A., Barker, O., Morris, G. B., Law, R. J., Slack, M., and Biggin, P. C. (2013) Toward an understanding of agonist binding to human Orexin-1 and Orexin-2 receptors with G-protein-coupled receptor modeling and site-directed mutagenesis Biochemistry 52, 8246-8260 10.1021/bi401119m
12. Heifetz, A., Morris, G. B., Biggin, P. C., Barker, O., Fryatt, T., Bentley, J., Hallett, D., Manikowski, D., Pal, S., Reifegerste, R., Slack, M., and Law, R. (2012) Study of human Orexin-1 and ?2 G-protein-coupled receptors with novel and published antagonists by modeling, molecular dynamics simulations, and site-directed mutagenesis Biochemistry 51, 3178-3197 10.1021/bi300136h
13. Wacker, D., Wang, C., Katritch, V., Han, G. W., Huang, X. P., Vardy, E., McCorvy, J. D., Jiang, Y., Chu, M., Siu, F. Y., Liu, W., Xu, H. E., Cherezov, V., Roth, B. L., and Stevens, R. C. (2013) Structural features for functional selectivity at serotonin receptors Science 340, 615-619 10.1126/science.1232808
14. Wang, C., Jiang, Y., Ma, J., Wu, H., Wacker, D., Katritch, V., Han, G. W., Liu, W., Huang, X. P., Vardy, E., McCorvy, J. D., Gao, X., Zhou, X. E., Melcher, K., Zhang, C., Bai, F., Yang, H., Yang, L., Jiang, H., Roth, B. L., Cherezov, V., Stevens, R. C., and Xu, H. E. (2013) Structural basis for molecular recognition at serotonin receptors Science 340, 610-614 10.1126/science.1232807
15. Shukla, A. K., Westfield, G. H., Xiao, K., Reis, R. I., Huang, L. Y., Tripathi-Shukla, P., Qian, J., Li, S., Blanc, A., Oleskie, A. N., Dosey, A. M., Su, M., Liang, C. R., Gu, L. L., Shan, J. M., Chen, X., Hanna, R., Choi, M., Yao, X. J., Klink, B. U., Kahsai, A. W., Sidhu, S. S., Koide, S., Penczek, P. A., Kossiakoff, A. A., Woods, V. L., Jr., Kobilka, B. K., Skiniotis, G., and Lefkowitz, R. J. (2014) Visualization of arrestin recruitment by a G-protein-coupled receptor Nature 512, 218-222 10.1038/nature13430
16. Brennan, P. E., Whitlock, G. A., Ho, D. K. H., Conlon, K., and McMurray, G. (2009) Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence Bioorg. Med. Chem. Lett. 19, 4999-5003 10.1016/j.bmcl.2009.07.063
17. Andrews, M. D., Green, M. P., Allerton, C. M. N., Batchelor, D. V., Blagg, J., Brown, A. D., Gordon, D. W., McMurray, G., Millns, D. J., Nichols, C. L., and Watson, L. (2009) Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT2C agonists Bioorg. Med. Chem. Lett. 19, 5346-5350 10.1016/j.bmcl.2009.07.133
18. Allerton, C. M. N., Andrews, M. D., Blagg, J., Ellis, D., Evrard, E., Green, M. P., Liu, K. K. C., McMurray, G., Ralph, M., Sanderson, V., Ward, R., and Watson, L. (2009) Design and synthesis of pyridazinone-based 5-HT2C agonists Bioorg. Med. Chem. Lett. 19, 5791-5795 10.1016/j.bmcl.2009.07.136
19. Siuciak, J. A., Chapin, D. S., McCarthy, S. A., Guanowsky, V., Brown, J., Chiang, P., Marala, R., Patterson, T., Seymour, P. A., Swick, A., and Iredale, P. A. (2007) CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity Neuropharmacology 52, 279-290 10.1016/j.neuropharm.2006.07.024
20. Kalgutkar, A. S., Dalvie, D. K., Aubrecht, J., Smith, E. B., Coffing, S. L., Cheung, J. R., Vage, C., Lame, M. E., Chiang, P., McClure, K. F., Maurer, T. S., Coelho, R. V., Jr., Soliman, V. F., and Schildknegt, K. (2007) Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2C receptor agonist for the treatment of obesity: role of metabolic activation Drug Metab. Dispos. 35, 848-858 10.1124/dmd.106.013649
21. Kalgutkar, A. S., Bauman, J. N., McClure, K. F., Aubrecht, J., Cortina, S. R., and Paralkar, J. (2009) Biochemical basis for differences in metabolism-dependent genotoxicity by two diazinylpiperazine-based 5-HT2C receptor agonists Bioorg. Med. Chem. Lett. 19, 1559-1563 10.1016/j.bmcl.2009.02.032
22. Fish, P. V., Brown, A. D., Evrard, E., and Roberts, L. R. (2009) 7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: Hit-to-lead optimization Bioorg. Med. Chem. Lett. 19, 1871-1875 10.1016/j.bmcl.2009.02.071
23. 2C agonist for the treatment of obesity Bioorg. Med. Chem. Lett. 20, 266-271 10.1016/j.bmcl.2009.10.112
24. Liu, K. K. C., Lefker, B. A., Dombroski, M. A., Chiang, P., Cornelius, P., Patterson, T. A., Zeng, Y., Santucci, S., Tomlinson, E., Gibbons, C. P., Marala, R., Brown, J. A., Kong, J. X., Lee, E., Werner, W., Wenzel, Z., Giragossian, C., Chen, H., and Coffey, S. B. (2010) Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity Bioorg. Med. Chem. Lett. 20, 2365-2369 10.1016/j.bmcl.2010.01.107
25. Ballesteros, J. A. and Weinstein, H. (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors Methods Neurosci. 25, 366-428 10.1016/S1043-9471(05)80049-7
26. Prioleau, C., Visiers, I., Ebersole, B. J., Weinstein, H., and Sealfon, S. C. (2002) Conserved Helix 7 Tyrosine Acts as a Multistate Conformational Switch in the 5HT2C Receptor. Identification of a Novel ?Locked-On? Phenotype and Double Revertant Mutations J. Biol. Chem. 277, 36577-36584 10.1074/jbc.M206223200
27. Rashid, M., Manivet, P., Nishio, H., Pratuangdejkul, J., Rajab, M., Ishiguro, M., Launay, J.-M., and Nagatomo, T. (2003) Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling Life Sci. 73, 193-207 10.1016/S0024-3205(03)00227-3
28. Deraet, M., Manivet, P., Janoshazi, A., Callebert, J., Guenther, S., Drouet, L., Launay, J.-M., and Maroteaux, L. (2005) The natural mutation encoding a C terminus-truncated 5-hydroxytryptamine2B receptor is a gain of proliferative functions Mol. Pharmacol. 67, 983-991 10.1124/mol.104.008268
29. Abul Muntasir, H., Takahashi, J., Rashid, M., Ahmed, M., Komiyama, T., Hossain, M., Kawakami, J., Nashimoto, M., and Nagatomo, T. (2006) Site-directed mutagenesis of the serotonin 5-hydroxytryptamine2C receptor: identification of amino acids responsible for sarpogrelate binding Biol. Pharm. Bull. 29, 1645-1650 10.1248/bpb.29.1645
30. Canal, C. E., Cordova-Sintjago, T. C., Villa, N. Y., Fang, L.-J., and Booth, R. G. (2011) Drug discovery targeting human 5-HT2C receptors: Residues S3.36 and Y7.43 impact ligand-Binding pocket structure via hydrogen bond formation Eur. J. Pharmacol. 673, 1-12 10.1016/j.ejphar.2011.10.006
31. Janoshazi, A., Deraet, M., Callebert, J., Setola, V., Guenther, S., Saubamea, B., Manivet, P., Launay, J.-M., and Maroteaux, L. (2007) Modified receptor internalization upon coexpression of 5-HT1B receptor and 5-HT2B receptors Mol. Pharmacol. 71, 1463-1474 10.1124/mol.106.032656
32. Steyaert, J. and Kobilka, B. K. (2011) Nanobody stabilization of G protein-coupled receptor conformational states Curr. Opin. Struct. Biol. 21, 567-572 10.1016/j.sbi.2011.06.011
33. Abdul-Hussein, S., Andrell, J., and Tate, C. G. (2013) Thermostabilisation of the serotonin transporter in a cocaine-bound conformation J. Mol. Biol. 425, 2198-2207 10.1016/j.jmb.2013.03.025
34. Tate, C. G. (2012) A crystal clear solution for determining G-protein-coupled receptor structures Trends Biochem. Sci. 37, 343-352 10.1016/j.tibs.2012.06.003
35. Farrens, D. L., Altenbach, C., Yang, K., Hubbell, W. L., and Khorana, H. G. (1996) Requirement of rigid-body motion of transmembrane helixes for light activation of rhodopsin Science (Washington, DC, U. S.) 274, 768-770 10.1126/science.274.5288.768
36. Gether, U., Lin, S., Ghanouni, P., Ballesteros, J. A., Weinstein, H., and Kobilka, B. K. (1997) Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor EMBO J. 16, 6737-6747 10.1093/emboj/16.22.6737
37. Trzaskowski, B., Latek, D., Yuan, S., Ghoshdastider, U., Debinski, A., and Filipek, S. (2012) Action of molecular switches in GPCRs-theoretical and experimental studies Curr. Med. Chem. 19, 1090-1109 10.2174/092986712799320556
38. Heifetz, A., Bodkin, M. J., and Biggin, P. C. (2015) Discovery of the First Selective, Nonpeptidic Orexin 2 Receptor Agonists J. Med. Chem. 58, 7928-7930 10.1021/acs.jmedchem.5b01394
39. Chen, Y. C. (2015) Beware of docking! Trends Pharmacol. Sci. 36, 78-95 10.1016/j.tips.2014.12.001
40. Heifetz, A., Schertler, G. F., Seifert, R., Tate, C. G., Sexton, P. M., Gurevich, V. V., Fourmy, D., Cherezov, V., Marshall, F. H., Storer, R. I., Moraes, I., Tikhonova, I. G., Tautermann, C. S., Hunt, P., Ceska, T., Hodgson, S., Bodkin, M. J., Singh, S., Law, R. J., and Biggin, P. C. (2015) GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1-2 September 2014 Naunyn-Schmiedeberg's Arch. Pharmacol. 388, 883 10.1007/s00210-015-1111-8
41. Kooistra, A. J., Leurs, R., de Esch, I. J., and de Graaf, C. (2014) From three-dimensional GPCR structure to rational ligand discovery Adv. Exp. Med. Biol. 796, 129-157 10.1007/978-94-007-7423-0-7
42. Rasmussen, S. G. F., DeVree, B. T., Zou, Y.-Z., Kruse, A. C., Chung, K.-Y., Kobilka, T.-S., Thian, F.-S., Chae, P.-S., Pardon, E., Calinski, D., Mathiesen, J. M., Shah, S. T. A., Lyons, J. A., Caffrey, M., Gellman, S. H., Steyaert, J., Skiniotis, G., Weis, W. I., Sunahara, R. K., and Kobilka, B. K. (2011) Crystal structure of the β2 adrenergic receptor-Gs protein complex Nature (London, U. K.) 477, 549-555 10.1038/nature10361
43. Rasmussen, S. G. F., Choi, H.-J., Rosenbaum, D. M., Kobilka, T. S., Thian, F. S., Edwards, P. C., Burghammer, M., Ratnala, V. R. P., Sanishvili, R., Fischetti, R. F., Schertler, G. F. X., Weis, W. I., and Kobilka, B. K. (2007) Crystal structure of the human β2 adrenergic G-protein-coupled receptor Nature (London, U. K.) 450, 383-387 10.1038/nature06325
44. Yarnitzky, T., Levit, A., and Niv, M. Y. (2010) Homology modeling of G-protein-coupled receptors with X-ray structures on the rise Curr. Opin Drug Discov Devel 13, 317-325
45. Andrews, M. D., Blagg, J., Brennan, P. E., Fish, P. V., Roberts, L. R., Storer, R. I., and Whitlock, G. A. (2008) Preparation of pyrimido[4,5-d]azepine derivatives as 5-HT2C agonists. WO2008117169, UK.